MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.

@article{Rho2014METAA,
  title={MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.},
  author={Jin Kyung Rho and Yun Jung Choi and Seon Ye Kim and Tae Won Kim and Eun Kyung Choi and Seon-Joo Yoon and Bu Man Park and Eunhye Park and Jong Hwan Bae and Chang Min Choi and Jae Cheol Lee},
  journal={Cancer research},
  year={2014},
  volume={74 1},
  pages={253-62}
}
In non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations, acquired resistance to EGFR-tyrosine kinase inhibitors (EGFR-TKI) can occur through a generation of bypass signals such as MET or AXL activation. In this study, we investigated the antitumor activity of NPS-1034, a newly developed drug that targets both MET and AXL, in NSCLC cells with acquired resistance to gefitinib or erlotinib (HCC827/GR and HCC827/ER, respectively). Characterization of H820 cells… CONTINUE READING